Prioritising the next generation of neurology diagnostics through rigorous assessment of biomarker candidates

Evaluated 280+ biomarker candidates across four neurological conditions: multiple sclerosis (MS), Alzheimer’s Disease AD, Parkinson’s Disease (PD), and traumatic brain injury (TBI).

Synthesised the research, commercial, and technical fact base to enable portfolio management activities

Worked with leading neuroscientists and key opinion leaders (KOLs) to critically evaluate findings

Identified 30+ promising biomarkers to be prioritised for further development

Provided near real-time updates to incorporate latest research in a rapidly advancing field of research